Entries |
Document | Title | Date |
20080234230 | Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator - Pharmaceutical composition for regulation of pancreatic juice secretion characterized by comprising a lisophosphatidic acid (LPA) receptor modulator. Since an LPA receptor modulator has an effect of regulating the secretion of pancreatic juice, a compound acting on this receptor is useful in treating diseases in association with disorders in pancreatic juice secretion. For example, an LPA receptor agonist is useful in treating and/or preventing pancreatic diseases and obesity, while an LPA receptor antagonist is useful in treating and/or preventing maldigestion, constipation, diarrhea and cibophobia. | 09-25-2008 |
20080287395 | Phospholipid Compositions for Contact Lens Care and Preservation of Pharmaceutical Compositions - The use of certain synthetic phospholipids to preserve pharmaceutical compositions from microbial contamination is described. The synthetic phospholipids have unique molecular arrangements wherein a phosphate group is linked to a quaternary ammonium functionality via a substituted-propenyl group, and the quaternary ammonium functionality is further linked to at least one long hydrocarbon chain. Such molecular arrangements are what make the phospholipids of formula (I) highly water soluble, e.g., the length of the hydrocarbon chain assists to maintain solubility and efficacy of the molecules for the uses described herein. The synthetic phospholipids described herein have been found to be particularly useful as antimicrobial preservatives for ophthalmic, otic and nasal pharmaceutical compositions, especially ophthalmic compositions. These compounds may also be utilized to disinfect contact lenses. The invention is based in-part upon a finding that the antimicrobial activity of the synthetic phospholipids is affected by the ionic strength of the compositions in which the compounds are contained. The provision of compounds having limited ionic strengths is therefore preferred. | 11-20-2008 |
20080300221 | Contact Lens Care Composition - The present invention relates to ophthalmic compositions such as contact lens care solutions, containing miltefosine. The present invention further relates to ophthalmic compositions or contact lens care systems containing miltefosine in combination with additional other active microbiocidal substances or proteases. Furthermore, the invention relates to the use of the compositions for the removal and eradication of protozoan parasites such as Acanthamoeba from contact lenses. | 12-04-2008 |
20080312187 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to methods of treating Alzheimer's Disease which utilize agents that increase neuronal phosphotidylinositol 4,5-biphosphate (PIP2), and to differentiated stem cell-based assay systems that may be used to identify agents that modulate phosphoinositide levels and thereby treat a variety of diseases. It is based, at least in part, on the discovery that edelfosine, an agent that increases PIP2 levels by inhibiting an enzyme that catalyzes PIP2 breakdown, decreases levels of neurotoxic A&bgr;42 peptide, particularly in cells expressing a mutant presenilin gene associated with Familial Alzheimer's Disease. | 12-18-2008 |
20090018105 | Means and Methods for the Treatment and Prevention of Allergic Diseases - The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization. Preferred in this context are edelfosine and miltefosine. In a particularly preferred embodiment, the present invention relates to the use of miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma. | 01-15-2009 |
20090124579 | Systems and Methods For Determination of Compounds for Stimulation or Inhibition of Neocalcification - Disclosed are systems and methods as may be used for development of compounds that can be utilized for prevention of pathological calcification. Disclosed are functional models can represent in great detail the first steps in protein-membrane interaction leading to calcification. Disclosed compounds include those that interfere with pathologic calcification processes and thus may be used as part of a formulation or composition for preventing pathological calcifications. Modeling methods and systems can include in vitro and/or in silico dynamic molecular modeling of biological materials including representative mineralization models in conjunction with substances that can affect normal or pathogenic calcification processes. Disclosed models can examine interactions of biological components involved in calcification including calcium, inorganic phosphate, phosphatidylserine, and annexin-5 protein. | 05-14-2009 |
20090291920 | DETECTION OF STEROID RECEPTORS ON CIRCULATING CARCINOMA CELLS AND TREATMENT - The expression of a steroid receptor from circulating carcinoma cells in a blood sample is detected by isolating the carcinoma cells from the blood sample, making an extract from the isolated carcinoma cells and then performing on the extract a sensitive immunoassay capable of detecting the carcinoma cell-associated steroid receptor. A positive result indicates the presence of the steroid receptor in the carcinoma cells. This method can be used to identify cancer patients who are likely to benefit from treatment with an endocrine therapeutic agent. | 11-26-2009 |
20090312286 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS - The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I) | 12-17-2009 |
20100069332 | Lipids containing omega-3 and omega-6 fatty acids - A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes. | 03-18-2010 |
20100105635 | COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASE ASSOCIATED WITH AMYLOIDOSIS THROUGH INHIBITION OF AMYLOID PROTEIN AGGREGATION AND PROMOTION OF AMYLOID PROTEIN DEGRADATION - It is an object of the present invention to provide a means for promoting amyloid protein degradation and a means for inhibiting amyloid protein aggregation. | 04-29-2010 |
20100144675 | Regulation of sGC Function by Corrin Derivatives - We disclose a method of activating soluble guanylyl cyclase (sGC) in a patient, comprising administering to the patient a composition comprising a corrin and a pharmaceutically-acceptable carrier. We also disclose a composition, comprising a corrin, an NO-independent sGC activator selected from the group consisting of BAY 41-2272, BAY 58-2667, HMR1766, YC-I, and S3448, and a pharmaceutically-acceptable carrier. | 06-10-2010 |
20100144676 | OLEYL PHOSPHOCHOLINE - The invention relates to the use of oleyl phosphocholine and oleyl-phospho-(N.N.-dimethyl-N-ethyl)-ethyl-ammonium for the long-term and continuous treatment of serious illnesses, such as cancer, leishmaniasis, ehrlichiosis, multiple sclerosis and psoriasis, in addition to other indications mentioned in the application. | 06-10-2010 |
20100152137 | Alkylphospholipids as active agents for prevention of plant pathogens - The invention relates to a process for controlling plant pathogens comprising the application of alkylphospholipids as active substances. Further, the invention relates to the use of alkylphospholipids for controlling plant pathogens, and to an agent for controlling plant pathogens containing an effective amount of at least one alkylphospholipid. | 06-17-2010 |
20100179106 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF - Compositions and methods for treating mitochondrial disorders are provided. The compositions include compounds having a mitochondrial targeting moiety, for example a lipophilic cation. Certain compounds are effective for increasing the ratio of phosphocreatine/creatine in a host, for example a mammal. Other compounds decrease the ratio of phophocreatine/creating in a host. An exemplary compound is defined by the following structure (Formula Ia): wherein R | 07-15-2010 |
20100204181 | N-HALOGENATED AMINO ACID FORMULATIONS COMPRISING PHOSPHINE OR AMINE OXIDES - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and a phosphine oxide or amine oxide. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding a phosphine oxide or amine oxide to said formulation. | 08-12-2010 |
20100273740 | Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses and Coronaviruses - Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents. | 10-28-2010 |
20100286093 | ANTI-INFLAMMATORY COMPOSITION CONTAINING DOCOSAHEXAENOYL LYSOPHOSPHATIDYLAMINE AS AN ACTIVE INGREDIENT - The present invention relates to an anti-inflammatory composition containing docosahexaenoyl lysophosphatidylamine as an active ingredient. Particularly, one of polyunsaturated lysophosphatidylcholines, docosahexaenoyl lysophosphatidylcholine inhibits intracellular NO generation mediated by lipopolysaccharide and suppresses zymosan A induced peritonitis in vivo, suggesting that it has excellent anti-inflammatory effect but has no cytotoxicity, so that it can be effectively used for prevention and treatment of inflammatory disease. | 11-11-2010 |
20100311692 | Pharmaceutical Formulation Containing Choline Alfoscerate - The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments. | 12-09-2010 |
20100331280 | Modulation of the Phospholipase A2 Pathway as a Therapeutic - There is provided a method of modifying vasoactivity by regulating a soluble Aβ pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble Aβ pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble Aβ pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble Aβ pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided. | 12-30-2010 |
20100331281 | PHOSPHOLIPID COMPOSITIONS AND USES THEREOF - We have discovered that phospholipids diundecanoyl (C11:0-C11:0) and dilauroyl (C12:0-C12:0) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor. We have also shown that administration of these lipids to diabetic mice reduces blood glucose levels. On the basis of these discoveries, the present invention features compositions that include these lipids and structurally related lipids. Also featured are methods of treating metabolic disorders and inflammatory bowel disease, lowering blood glucose levels, and increasing LRH-1 receptor activity in a subject by administration of these lipids. | 12-30-2010 |
20100331282 | PYRIDINE DERIVATIVE CONTAINING ((PHOSPHONOOXY)METHYL)PYRIDINIUM RING, AND ANTIFUNGAL AGENT CONTAINING THESE DERIVATIVE - The present invention provides an antifungal agent that has excellent antifungal action, and is also superior in terms of its properties, and particularly its solubility in water and safety in an aqueous solution, and its in vivo pharmacokinetics and safety. According to the present invention, there is provided a compound represented by the following formula (I), or a salt thereof: | 12-30-2010 |
20110003772 | USE OF SPHINGOLIPIDS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, INSULIN RESISTANCE AND METABOLIC SYNDROME - The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and/or a medicament for the treatment of insulin resistance, diabetes mellitus type 2 and/or metabolic syndrome. In particular, the invention relates to the use of a sphingolipid with the general formula (I): | 01-06-2011 |
20110003773 | USING FULLERENES TO ENHANCE AND STIMULATE HAIR GROWTH - Described herein are methods for treating lack of hair growth or a reduction or loss of existing hair by stimulating and/or restoring hair growth, or preventing hair loss. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a fullerene. | 01-06-2011 |
20110015154 | SUPPORTING ACETYLCHOLINE FUNCTION - This document provides methods and materials related to regulating inflammatory pathways. For example, compositions and kits containing two or more of an anticholinesterase compound, a choline compound, and a carnitine compound and methods for using the compositions and kits described herein to support acetylcholine function to regulate one or more inflammatory pathways are provided. | 01-20-2011 |
20110065670 | Skin Beautifier - A skin beautifier contains sphingomyelin, which is a phospholipid, as an effective ingredient. In addition, skin-beautifying food or feed contains sphingomyelin as an effective ingredient. The present invention provides a skin beautifier and skin-beautifying food or feed supplying effects on beauty, such as skin-moisturizing and protecting effects, skin-roughness-preventing and improving effects, and a wrinkle-preventing effect, by oral ingestion thereof. | 03-17-2011 |
20110152218 | CRYSTALLINE PHOSPHOLIPID, METHOD FOR ITS PRODUCTION AND USE IN TREATING DAMAGED TISSUE - The present invention provides phospholipid in a crystalline form, a method for its preparation, compositions comprising it and its use in the treatment of damaged tissue. | 06-23-2011 |
20110207703 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF - Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. | 08-25-2011 |
20110212921 | SYNTHESIS AND FORMULATIONS OF SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF - Disclosed herein are formulations and methods of manufacture of compounds of formula (E): | 09-01-2011 |
20110237548 | SYNERGISTIC COMPOSITION AND METHOD OF RETARDING AND AMELIORATING PHOTO INDUCED RETINAL DAMAGE AND CATARACTS WHILE AMELIORATING DRY EYE SYNDROME USING OMEGA CHOLINE - A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases. | 09-29-2011 |
20110263531 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS - The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization and/or activation. Preferred in this context are Edelfosine, Miltefosine and Perifosine. In a particularly preferred embodiment, the present invention relates to the use of Miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma, atopic dermatitis and mastocytosis. | 10-27-2011 |
20110275598 | COSMETIC USE OF PROANTHOCYANIDIN A2 - The use of proanthocyanidin A2 and of its complexes with phospholipids for the reshaping treatment of the breast and the anti-age treatment of the neck and the décolleté is described. | 11-10-2011 |
20120065167 | DOMPERIDONE AT A LOW DAILY DOSE FOR USE IN THE TREATMENT OR PREVENTION OF A DISEASE ASSOCIATED WITH AN ALTERATION OF THE IMMUNE RESPONSE - The invention relates to the use of domperidone or a pharmaceutically acceptable salt thereof at low doses to prevent and/or treat a disease associated with an alteration of the immune response such as Leishmaniosis. | 03-15-2012 |
20120077780 | Fat Accumulation Inhibitor and Method of Use Thereof - The present disclosure relates to a method of inhibiting a fat accumulation for a fat cell in a subject, which includes administering a fat accumulation inhibitor for a fat cell which includes a milk-derived phospholipid as an active ingredient to the subject. The present disclosure also relates to a method of inhibiting a visceral fat accumulation in a subject, which includes administering the visceral fat accumulation inhibitor which includes a sphingosine-containing phospholipid as an active ingredient to the subject. The present disclosure also relates to a method of accelerating increase and/or inhibiting decrease of an adiponectin concentration in blood, which includes administering an agent which includes a sphingosine-containing phospholipid as an active ingredient to the blood. The present disclosure also relates to a method of inhibiting a fat accumulation for a fat cell in a subject, which includes administering a milk-derived phospholipid to a subject. | 03-29-2012 |
20120108546 | SYNERGISTIC ANTIMICROBIAL COMPOSITION - A synergistic antimicrobial composition comprising:
| 05-03-2012 |
20120115814 | Liquid Pharmaceutical Form Of Alkylphosphocholine And Method For Preparing Same - The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it is necessary can be achieved by adding a pH adjuster. The composition has a good storage stability and it is suitable for local application on the different organs of the body. The inventions relates also to a method for producing the same pharmaceutical form. | 05-10-2012 |
20120129808 | BLOOD COAGULATION REACTION INHIBITOR - The present invention is a blood coagulation reaction inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The present invention is also a thrombin generation inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The blood coagulation reaction inhibitor and the thrombin generation inhibitor of the present invention are useful as an antithrombotic agent, a clinical laboratory test reagent for the blood coagulation-fibrinolysis system, and the like. | 05-24-2012 |
20120208783 | Medicine, Food And Drink Or Feed Containing Sphingomyelin - It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk. | 08-16-2012 |
20120232034 | VESICULAR FORMULATIONS - Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea. | 09-13-2012 |
20120238527 | ORGANOPHOSPHORUS DERIVATIVES AND USE THEREOF AS UNCOUPLING AGENTS - The present invention relates to an organophosphonium derivative of the mean general formula (1), where n is a number comprised between 4 and 20, preferably between 5 and 10, m is a number between 0 and 10, preferably between 0 and 1, and Y is an anion. | 09-20-2012 |
20120277187 | Agent for Preventing Infection - An agent for preventing an infection with an influenza virus or a food or drink for preventing infection with an influenza virus is provided. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which comprises a fat globule membrane component as an active ingredient. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which comprises a sphigosine-containing phospholipid and/or a derivative thereof, particularly sphingomyelin, as an active ingredient. | 11-01-2012 |
20120309716 | Motor Function Improver - Provided are a motor function improver, an endurance improver, a muscle strength improver, a muscle strength deterioration suppressor, an anti-fatigue agent, a mitochondrial function improver, an energy consumption promoter, and a lipid combustion promoter which contain a sphingomyelin as an active ingredient. | 12-06-2012 |
20120329757 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis - Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided. | 12-27-2012 |
20120329758 | Combined Treatment Utilizing VB-201 - Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed. | 12-27-2012 |
20130079307 | MEDICINE, FOOD AND DRINK OR FEED CONTAINING SPHINGOMYELIN - It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk. | 03-28-2013 |
20130143842 | STABLE AQUEOUS COMPOSITIONS COMPRISING BIOACTIVE CREATINE SPECIES - Compositions containing one or more bioactive forms of creatine, which are aqueous compositions in which the one or more bioactive forms of creatine do not appreciably degrade into creatinine. Also are methods for providing various beneficial effects which comprise administering aqueous compositions comprising at least one creatinol O-phosphate species to a mammalian subject, either chronically or acutely. | 06-06-2013 |
20130150327 | COMPOSITION FOR PREVENTING HAIR LOSS OR STIMULATING HAIR GROWTH - There is provided a composition for preventing hair loss or stimulating hair growth, the composition including phospholipids as an effective component, and more preferably, a composition for preventing hair loss or stimulating hair growth, the composition including phospholipids that are extracted from animals as an effective component. | 06-13-2013 |
20130172294 | Treatment with VB-201 - Unit dosage forms comprising between 1 mg and 100 mg VB-201 and a pharmaceutically acceptable carrier, and formulated for oral administration, are disclosed herein, as well as treatment regimens comprising oral administration of VB-201 once or twice daily for treating an inflammatory disease or disorder. | 07-04-2013 |
20130225525 | Combined Treatment Utilizing VB-201 - Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed. | 08-29-2013 |
20130225526 | MEDICINE, FOOD AND DRINK OR FEED CONTAINING SPHINGOMYELIN - It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk. | 08-29-2013 |
20130231305 | Method of Modulating Protein 14-3-3 Functionality By Facilitating or Inhibiting Phosphorylation - The present invention relates to a method of modulating cellular activity. More particularly, the present invention provides a method of modulating apoptosis by modulating protein 14-3-3 phosphorylation and, thereby its functionality. The present invention still further extends to methods for identifying agents capable of modulating protein 14-3-3 phosphorylation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted cellular activity, such as unwanted cell survival. | 09-05-2013 |
20130244981 | SYNERGISTIC COMPOSITION AND METHOD OF RETARDING AND AMELIORATING PHOTO INDUCED RETINAL DAMAGE AND CATARACTS WHILE AMELIORATING DRY EYE SYNDROME USING OMEGA CHOLINE - A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases. | 09-19-2013 |
20130244982 | CONJUGATES OF A PHOSPHOLIPID AND A DRUG FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by PLA | 09-19-2013 |
20130252923 | SKIN-BEAUTIFYING AGENT - A skin-beautifying agent, food, beverage, or feed for skin-beautification which has cosmetic effects such as moisturizing and beautifying the skin as well as preventing skin roughness and wrinkles by oral intake. Also described is a skin-beautifying agent containing a milk-derived phospholipid as an effective ingredient, and to provide food, beverage, or feed for skin- beautification containing the skin-beautifying agent. The milk-derived phospholipid is preferably a composition prepared from milk or milk material containing 40 to 70% by weight of lipid in a total solid content and containing 30% or more by weight of milk-derived phospholipid. | 09-26-2013 |
20130267480 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 10-10-2013 |
20130274228 | CONCOMITANT DRUG FOR IMPROVING COGNITIVE FUNCTION - The present invention aims to provide a medicament and/or food having a cognitive function improving effect, and a method of improving the cognitive function. | 10-17-2013 |
20130281404 | COMPOSITION CONTAINING 2-ACYL-LYSOPHOSPHATIDYLSERINE AND METHOD FOR PRODUCING THE SAME - The present invention provides a method for producing a composition containing 2-acyl-lysophosphatidylserine, including (a) a step of obtaining a composition containing phosphatidylserine by allowing phospholipase D to act on a raw material containing phosphatidylcholine in the presence of serine and (b) a step of obtaining a composition containing 2-acyl-lysophosphatidylserine by allowing phospholipase A1 to act on the composition containing phosphatidylserine in the presence of one or more additives selected from the group consisting of the following (I), (II), and (III), in which (I) one or more salts selected from the group consisting of sulfate salts, phosphate salts, nitrate salts, citrate salts, and tartarate salts of monovalent cations, (II) a gum, and (III) an emulsifier. | 10-24-2013 |
20130281405 | USE OF PC-NSAIDS TO TREAT AND/OR PREVENT PULMONARY INFLAMMATION - Aerosolizable compositions of nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with zwitterionic phospholipids in an aqueous carrier are used for treating lung injury (LI), pulmonary inflammation, and/or airway hyper-responsiveness (AHR). Methods for administering the compositions including orally, parenterally, intra-tracheally, and intra-pulmonarily protocols, especially intra-tracheally and intra-pulmonarily protocols, where the PC-NSAID compositions reduce lung injury (LI), pulmonary inflammation, and/or airway hyper-responsiveness (AHR). | 10-24-2013 |
20140088043 | OMEGA-3 COMPOSITIONS - The present invention relates to compositions comprising omega-3 fatty acid derivatives, and in particular to compositions comprising omega-3 phospholipids in combination with other omega-3 derivatives. | 03-27-2014 |
20140100191 | Vesicular Formulations - Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea. | 04-10-2014 |
20140100192 | Pharmaceutical Formulation Containing Choline Alfoscerate - The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments. | 04-10-2014 |
20140135289 | METHOD FOR PREVENTING BRAIN ATROPHY - The present invention provides brain atrophy prevention agent comprising a phospholipid containing a highly unsaturated fatty acid as a constituent fatty acid, as an active ingredient. | 05-15-2014 |
20140274956 | LIPIDOMICS OF FAMILIAL LONGEVITY - The disclosure relates to method of typing a sample from an individual as a sample from an individual with an increased life expectancy, an average life expectancy or a reduced life expectancy. The typing is based on a comparison of a level of lipid species in a sample of the individual to a level of lipid species in a reference. The disclosure further relates to a composition comprising lipid species for use in increasing life expectancy of an individual. | 09-18-2014 |
20140349967 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 11-27-2014 |
20150057249 | Vesicular Formulations - The present invention relates to vesicular formulations for the treatment of rosacea. It also relates to a method of treating rosacea comprising administering a vesicular formulation according to the invention. | 02-26-2015 |
20150065460 | Biomarkers Related to Insulin Resistance and Methods Using the Same - Biomarkers relating to pancreatic Beta-cell function, pancreatic Beta-cell glucose sensitivity, insulin resistance, and/or pancreatic Beta-cell-related disorders are provided. Methods based on the same biomarkers are also provided. | 03-05-2015 |
20150065461 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint - The present invention relates to vesicular formulations for use in the treatment of pain and/or reduced mobility associated with a loss of lubrication and/or structural integrity and/or swelling of a collagen structure. It also relates to a method of treating pain such as joint pain or tendonitis comprising topically administering a vesicular formulation according to the invention. | 03-05-2015 |
20150320773 | TREATMENT OF INFLAMMATION - Disclosed herein are methods of treating an inflammatory disease or disorder, as well as pharmaceutical compositions and kits useful for treating an inflammatory disease or disorder. The methods, compositions and kits utilize at least one agent, the at least one agent being capable of exhibiting at least two activities selected from the group consisting of: a) inhibiting CD 14 activity and/or a signaling pathway associated with CD 14 activity; b) inhibiting TLR2 activity and/or a signaling pathway associated with TLR2 activity; and c) inhibiting monocyte chemotaxis. | 11-12-2015 |
20150328193 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS - Embodiments disclosed herein provide combinatorial compositions and methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, e.g., lymphangioleiomyomatosis (LAM), LAM/TSC or treating and/or management of tuberous sclerosis complex (TSC) using combination drug therapy comprising rapamycin and at least one of SCH-202676 hydrobromide, danusertib (PHA-739358), AZ-960, SB-590885, Thimerosal, ionomycin, U-73343, PAF C16, BX912, and Chlorambucil. In addition, methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, or treating and/or management of tuberous sclerosis complex (TSC) using other known drugs are provided. | 11-19-2015 |
20150335664 | METHODS AND MATERIALS FOR REDUCING ORGAN TRANSPLANT REJECTION OR ISCHEMIC/REPERFUSION INJURY IN A SUBJECT - Methods and materials for reducing organ transplant rejection or minimizing ischemia or ischemia/reperfusion injury in a subject are described. The methods include administering a fat emulsion before or after the organ transplant or before, at the onset of, or after the ischemic event. | 11-26-2015 |
20150342971 | SPHINGOMYELIN-CONTAINING SUPPLEMENT - A solid supplement comprising the following components (A) and (B):
| 12-03-2015 |
20150344967 | PREDICTING LIKELIHOOD OF RESPONSE TO COMBINATION THERAPY - Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer. | 12-03-2015 |
20160016981 | AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID, PHOSPHONIC ACID AND CARBOXYLIC ACID DERIVATIVES AND THEIR MEDICAL USE - The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder. | 01-21-2016 |
20160038507 | Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment - Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: | 02-11-2016 |
20160067295 | WALNUT EXTRACTS FOR NUTRACEUTICAL APPLICATIONS - The invention describes to walnut oil extracts that have increased amounts of enriched in phospholipids, especially phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidylinositol (PI) relative to walnut oil found in naturally occurring walnuts. It has been found that there are synergistic therapeutic effects when PE/PC and/or PI are combined. | 03-10-2016 |
20160136192 | METHODS AND COMPOSITIONS FOR ENHANCING COGNITIVE PERFORMANCE - Compositions including an effective amount of each of phosphatidyl serine, choline, and oleic acid, and methods for improving cognitive performance that include administering such compositions to a subject, are described herein. The compositions can be nutritional compositions such as bars or liquids suitable for oral administration. The combination of phosphatidyl serine, choline, and oleic acid provides synergistic or complimentary modes of action that improve the overall effect of these compounds. | 05-19-2016 |
20160136290 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles - The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds. | 05-19-2016 |